- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07556159
Um Estudo que Avalia as Características da Doença e os Resultados em Participantes com Asma na Prática Clínica de Rotina (AIRITY)
<p>Um estudo híbrido transversal e prospetivo para avaliar as características do paciente, a carga da doença, o controlo da doença, os fenótipos, os endotipos e os resultados num contexto real em pacientes com asma</p>
The main aim of the study to describe the characteristics of participants with asthma across the spectrum of disease severity, including sociodemographic and clinical characteristics, treatment and disease burden, biomarkers, and both disease-specific and generic health-related quality of life.
The study consists of two parts: a cross-sectional study, and a prospective follow-up evaluate changes in disease trajectories in participants with asthma.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Trial Transparency email recommended-Toll free for US & Canada
- Número de telefone: 6 800-633-1610
- E-mail: Contact-US@sanofi.com
Locais de estudo
-
-
Bayern (Bavaria)
-
München, Bayern (Bavaria), Alemanha, 85039
- Recrutamento
- Investigational Site Number: 276503
-
-
North Rhine-Westphalia
-
Bonn, North Rhine-Westphalia, Alemanha, 53119
- Recrutamento
- Investigational Site Number: 276505
-
-
Saxony
-
Hohenstein-Ernstthal, Saxony, Alemanha, 09337
- Recrutamento
- Investigational Site Number: 276501
-
-
Schleswig-Holstein
-
Schleswig, Schleswig-Holstein, Alemanha, 24837
- Recrutamento
- Investigational Site Number: 276502
-
-
-
-
Alberta
-
Calgary, Alberta, Canadá, T3R 1W7
- Recrutamento
- Investigational Site Number: 124203
-
-
Ontario
-
Windsor, Ontario, Canadá, N8X 2G1
- Recrutamento
- Investigational Site Number: 124201
-
-
Quebec
-
Trois-Rivières, Quebec, Canadá, G8T7A1
- Recrutamento
- Investigational Site Number: 124204
-
-
-
-
-
Madrid, Espanha, 28034
- Recrutamento
- Investigational Site Number: 724408
-
-
-
-
Alabama
-
Bessemer, Alabama, Estados Unidos, 35022
- Recrutamento
- Trinity Clinical Research, LLC - Bessemer - Site Number: 840150
-
-
Arizona
-
Chandler, Arizona, Estados Unidos, 85224
- Retirado
- Chandler Clinical Trials - Site Number: 840106
-
Mesa, Arizona, Estados Unidos, 85206
- Ativo, não recrutando
- Del Sol Research Management, LLC - Mesa - Site Number: 840123
-
Scottsdale, Arizona, Estados Unidos, 85254
- Recrutamento
- Orso Health - Scottsdale - Site Number: 840133
-
Sun City, Arizona, Estados Unidos, 85351
- Ativo, não recrutando
- Sun City Clinical Trials - Elite - Site Number: 840120
-
-
California
-
California City, California, Estados Unidos, 91107
- Ativo, não recrutando
- FOMAT - Huntington Asthma & Allergy Center - Site Number: 840158
-
La Palma, California, Estados Unidos, 90623
- Ativo, não recrutando
- Imax Clinical Trials - Site Number: 840109
-
Los Angeles, California, Estados Unidos, 90017
- Ativo, não recrutando
- Downtown LA Research - Site Number: 840161
-
Newport Beach, California, Estados Unidos, 92663
- Ativo, não recrutando
- Newport Native MD, Inc. - Site Number: 840101
-
Pasadena, California, Estados Unidos, 91101
- Ativo, não recrutando
- Pasadena Clinical Trials - Site Number: 840116
-
Tarzana, California, Estados Unidos, 91356
- Retirado
- Valiance Clinical Research (JPJ Research) - Site Number: 840135
-
Walnut Creek, California, Estados Unidos, 94598
- Ativo, não recrutando
- Clinical Research of California - Site Number: 840145
-
-
Florida
-
Altamonte Springs, Florida, Estados Unidos, 32701
- Ativo, não recrutando
- Cornerstone Research Institute, LLC - Site Number: 840152
-
Boca Raton, Florida, Estados Unidos, 33431
- Ativo, não recrutando
- 3SYNC Research - Boca Raton - Site Number: 840148
-
Brandon, Florida, Estados Unidos, 33511
- Ativo, não recrutando
- Meris Clinical Research - Site Number: 840167
-
Greenacres City, Florida, Estados Unidos, 33467
- Ativo, não recrutando
- Finlay Medical Research - Site Number: 840107
-
Miami, Florida, Estados Unidos, 33126
- Ativo, não recrutando
- EMDA Clinical Research - Site Number: 840113
-
Miami, Florida, Estados Unidos, 33126
- Ativo, não recrutando
- Finlay Medical Research - Miami - Site Number: 840110
-
Miami, Florida, Estados Unidos, 33130
- Ativo, não recrutando
- Care Research Inc. - Site Number: 840103
-
Miami, Florida, Estados Unidos, 33142
- Ativo, não recrutando
- L&A Morales Healthcare, Inc - Site Number: 840102
-
Miami, Florida, Estados Unidos, 33145
- Ativo, não recrutando
- MedOne Clinical Research - Site Number: 840122
-
Miami, Florida, Estados Unidos, 33155
- Ativo, não recrutando
- D&H National Research Centers INC - Site Number: 840128
-
Miami, Florida, Estados Unidos, 33173
- Ativo, não recrutando
- Research Institute Of South Florida - Site Number: 840149
-
Miami, Florida, Estados Unidos, 33174
- Ativo, não recrutando
- Valencia Medical & Research Center, Corp - Site Number: 840153
-
Miami, Florida, Estados Unidos, 33186
- Ativo, não recrutando
- Correa Research Center, Inc. - Site Number: 840141
-
Miami Gardens, Florida, Estados Unidos, 33014
- Ativo, não recrutando
- Pro Care Research Center - Site Number: 840143
-
Miami Lakes, Florida, Estados Unidos, 33014
- Ativo, não recrutando
- 3SYNC Research - Miami Lakes - Site Number: 840146
-
Miami Lakes, Florida, Estados Unidos, 33014
- Ativo, não recrutando
- Deluxe Health Center - Site Number: 840117
-
Miami Lakes, Florida, Estados Unidos, 33016
- Ativo, não recrutando
- MedQuest Translation Sciences, LLC - Site Number: 840162
-
North Miami Beach, Florida, Estados Unidos, 33169
- Ativo, não recrutando
- Biscayne Clinical Research - Site Number: 840157
-
Palm Springs, Florida, Estados Unidos, 33406
- Ativo, não recrutando
- CTMD Research, Inc - Site Number: 840147
-
Plantation, Florida, Estados Unidos, 33317
- Ativo, não recrutando
- Edward Jenner Research Group, LLC - Site Number: 840169
-
Port Saint Lucie, Florida, Estados Unidos, 34986
- Ativo, não recrutando
- Mark J. Pamer D.O., LLC - Site Number: 840121
-
Tamarac, Florida, Estados Unidos, 33321
- Ativo, não recrutando
- TBC Research Corp - Site Number: 840132
-
Tampa, Florida, Estados Unidos, 33613
- Ativo, não recrutando
- Avita Clinical Research - Tampa - Site Number: 840125
-
West Palm Beach, Florida, Estados Unidos, 33409
- Ativo, não recrutando
- Palm Beach Medical & Research Center, Inc. - Site Number: 840165
-
-
Georgia
-
Columbus, Georgia, Estados Unidos, 31904
- Ativo, não recrutando
- The Allergy Center at Brookstone - Site Number: 840114
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60616
- Ativo, não recrutando
- Next Innovation Clinical Research - Chicago - Site Number: 840159
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40509
- Ativo, não recrutando
- Bluegrass Allergy Care - Lexington - Site Number:840112
-
-
Maryland
-
Columbia, Maryland, Estados Unidos, 21045
- Recrutamento
- Columbia Medical Practice - Site Number: 840172
-
Rockville, Maryland, Estados Unidos, 20854
- Ativo, não recrutando
- Velocity Clinical Research - Rockville - Site Number: 840163
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- Recrutamento
- University of Michigan - Ann Arbor - Site Number: 840140
-
-
Montana
-
Missoula, Montana, Estados Unidos, 59808
- Ativo, não recrutando
- Montana Medical Research - Site Number: 840137
-
-
Nebraska
-
Papillion, Nebraska, Estados Unidos, 68046
- Ativo, não recrutando
- Primary Clinical Research, LLC - Papillion - Site Number: 840168
-
-
New Jersey
-
Sewell, New Jersey, Estados Unidos, 08080
- Ativo, não recrutando
- MedCorps Asthma and Pulmonary Specialists LLC - Sewell - Site Number: 840136
-
-
New York
-
Cortland, New York, Estados Unidos, 13045
- Ativo, não recrutando
- Finger Lakes Medical Research, PLLC - Site Number: 840155
-
New Windsor, New York, Estados Unidos, 12553
- Ativo, não recrutando
- Mid Hudson Medical Research, PLLC - Site Number: 840139
-
New York, New York, Estados Unidos, 10029
- Ativo, não recrutando
- Icahn School of Medicine at Mount Sinai - Center for Advanced Medicine - Site Number: 840119
-
-
North Carolina
-
Asheville, North Carolina, Estados Unidos, 28801
- Ativo, não recrutando
- Allergy Partners of Western North Carolina - Site Number: 840131
-
Gastonia, North Carolina, Estados Unidos, 28054-7489
- Ativo, não recrutando
- Clinical Research of Gastonia (CRG) - Site Number: 840160
-
Greenville, North Carolina, Estados Unidos, 27834-2849
- Recrutamento
- East Carolina University Physicians - Pulmonary and Critical Care Medicine - Site Number: 840142
-
-
Ohio
-
Lima, Ohio, Estados Unidos, 45801
- Ativo, não recrutando
- NexGen Research - Site Number: 840154
-
Toledo, Ohio, Estados Unidos, 43617
- Ativo, não recrutando
- Toledo Institute of Clinical Research Inc - Site Number: 840105
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15241
- Ativo, não recrutando
- Allergy and Clinical Immunology Associates - Site Number: 840127
-
-
South Carolina
-
Rock Hill, South Carolina, Estados Unidos, 29732
- Ativo, não recrutando
- Clinical Research of Rock Hill - Site Number: 840115
-
-
Tennessee
-
Tennessee City, Tennessee, Estados Unidos, 30909
- Ativo, não recrutando
- Allergy Associates, PA dba Allergy, Asthma and Sinus Center - Site Number: 840144
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75235
- Ativo, não recrutando
- Southwest Family Medicine Associates - Site Number: 840126
-
El Paso, Texas, Estados Unidos, 79902
- Ativo, não recrutando
- El Paso Pulmonary Association (EPPA) - West El Paso - Site Number: 840108
-
Houston, Texas, Estados Unidos, 77090
- Ativo, não recrutando
- Lumi Research - Site Number: 840156
-
Houston, Texas, Estados Unidos, 77099
- Ativo, não recrutando
- Pioneer Research Solutions - Site Number: 840104
-
Hurst, Texas, Estados Unidos, 76054
- Ativo, não recrutando
- Lumi Research - Hurst - Site Number: 840164
-
Tomball, Texas, Estados Unidos, 77081
- Ativo, não recrutando
- DM Clinical - Tomball - Site Number: 840130
-
-
Washington
-
Bellingham, Washington, Estados Unidos, 98225
- Ativo, não recrutando
- Bellingham Asthma, Allergy & Immunology Clinic - Site Number: 840138
-
-
-
-
Brittany Region
-
Brest, Brittany Region, França, 29200
- Recrutamento
- Investigational Site Number: 250603
-
-
Occitanie
-
Lunel, Occitanie, França, 34400
- Recrutamento
- Investigational Site Number: 250612
-
Toulouse, Occitanie, França, 31059
- Recrutamento
- Investigational Site Number: 250607
-
-
Pays de la Loire Region
-
La Roche-sur-Yon, Pays de la Loire Region, França, 85000
- Recrutamento
- Investigational Site Number: 250613
-
-
Île-de-France Region
-
Argenteuil, Île-de-France Region, França, 95100
- Recrutamento
- Investigational Site Number: 250616
-
Créteil, Île-de-France Region, França, 94010
- Recrutamento
- Investigational Site Number: 250609
-
-
-
-
-
Niigata, Japão
- Recrutamento
- Investigational Site Number: 392707
-
-
Fukuoka
-
Kitakyushu-Shi, Fukuoka, Japão, 802-0083
- Recrutamento
- Investigational Site Number: 392705
-
-
Kagawa-ken
-
Takamatsu, Kagawa-ken, Japão, 761-8073
- Recrutamento
- Investigational Site Number: 392702
-
-
Saga-ken
-
Saga, Saga-ken, Japão, 849-8501
- Recrutamento
- Investigational Site Number: 392711
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japão, 113-8431
- Recrutamento
- Investigational Site Number: 392710
-
tabashi City, Tokyo, Japão, 173-8610
- Recrutamento
- Investigational Site Number: 392709
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Enrollment into Part 1 is planned to achieve a balanced distribution of participants across participating regions, to the extent feasible. In addition, enrollment is intended to include pediatric participants, adolescents, and adults. Enrollment into Part 2 is planned to achieve a balanced distribution of participants across participating regions, to the extent feasible.
Descrição
Inclusion Criteria:
Applicable for Part 1 participants:
- Age 6 years and older, at the time of signing the informed consent
- Physician diagnosis of asthma for at least 12 months
- Existing treatment with low, medium, or high dose ICS and other asthma therapies as reflected in GINA 2-5 steps
- Participant or legally authorized representative (where applicable) has consented to participate
Applicable for Part 2 participants:
- Age 18 years and older, at the time of signing the informed consent.
- Physician diagnosis of asthma for at least 12 months
- Existing treatment with low or medium ICS and other asthma therapies as reflected in GINA 2-4 steps
- Participant or legally authorized representative (where applicable) has consented to participate
- Participants must meet the criteria for at least one of the cohorts below:
A) Asthma control cohorts
- ACQ-5 >= 1.5
- ACQ-5 < 1.5 (B) Type-2 biomarker cohorts
- Elevated T2 biomarkers (B1: Type-2-high cohort)
- Low T2 biomarkers (B2: Type-2-low cohort)
Participants are excluded from the study if any of the following criteria apply (applicable for both Part 1 and Part 2 participants):
- Current diagnosis of chronic obstructive pulmonary disease (COPD) or congestive heart failure
- Participants with moderate/severe cognitive impairment.
- Participants with moderate/severe cardiac disease.
- Participants on immunosuppressive medication for a chronic condition.
- Participation in other interventional and noninterventional clinical study (currently or in the past 3 months)
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Part-1: Participants With Asthma
Participants receiving treatment with low-, medium-, or high-dose inhaled corticosteroids (ICS) and/or biologic therapies as part of standard of care (SoC) for the management of asthma in routine clinical practice. |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
|
Part-2: A1- Uncontrolled Asthma Cohort
Participants receiving SoC with Asthma Control Questionnaire-5 (ACQ-5) threshold of greater than or equal to (>=)1.5 |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
|
Part-2: A2- Controlled Asthma Cohort
Participants receiving SoC with Asthma Control Questionnaire-5 (ACQ-5) threshold of less than (<)1.5 |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
|
Part-2: B1- Type-2 (T2) High Asthma Cohort
Participants receiving SoC with elevated T2 biomarkers |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
|
Part-2: B2- Type-2 Low Asthma Cohort
Participants receiving SoC with low T2 biomarkers |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Part 1: Descriptive Characterization of Participants With Asthma Across the Spectrum of Severities
Prazo: Part 1: At baseline
|
Descriptive Statistical Analyses may include sociodemographic and clinical characteristics, comorbidities, exacerbation history, medication burden, biomarkers and lung function. |
Part 1: At baseline
|
|
Part 1: ACQ-5 Scores to Evaluate Characteristics of Participants With Asthma
Prazo: Part 1: At baseline
|
ACQ-5 is a 5-question survey. The five ACQ-5 questions are scored on a 6-point scale (0 = good control, 6 = poor control), and the overall score is the mean of the five responses. Participant's scores are then classified into three prescribed groups as having well-controlled asthma (score ≤ 0.75); partially controlled asthma (score 0.75-1.5), or not well controlled asthma (score >1.5). A change in ACQ-5 score of 0.5 is considered the minimal clinically important difference (MCID) |
Part 1: At baseline
|
|
Part 1: Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ) Scores to Evaluate Characteristics of Participants With Asthma
Prazo: Part 1: At baseline
|
The Asthma Quality of Life Questionnaire (AQLQ) includes 32 items, The mini-AQLQ is a reduced version of the AQLQ which includes 15 items. The questions correspond to 4 dimensions of health: symptoms (5 items), limitation of usual activities (4 items), emotional function (3 items) and environmental stimuli (3 items). The response options for each item are on an equidistant scale of 7 points, where 1 corresponds to the maximum disability and 7 to the absence of disability. Higher scores indicating better quality of life (less impairment) and lower scores indicating worse quality of life (greater impairment). |
Part 1: At baseline
|
|
Part 1: Physician Global Assessment of Asthma Severity and Symptom Control
Prazo: Part 1: At baseline
|
Asthma severity, asthma control, and comorbidity will be assessed using three global impression of severity items: Physician Global Impression of Severity (PhGIS) - asthma severity. PhGIS - asthma control, and PhGIS - comorbidity. |
Part 1: At baseline
|
|
Part 2: Descriptive Statistical Analysis of Difference in Asthma Symptom Control (ACQ-5) Between Part 2 Cohorts A1 and A2
Prazo: Part 2: At Weeks 52 and 104
|
Data on participant's asthma symptoms and control will be collected via the ACQ-5, 5-question survey. The five ACQ-5 questions are scored on a 6-point scale (0 = good control, 6 = poor control), and the overall score is the mean of the five responses. Participant's scores are then classified into three prescribed groups as having well-controlled asthma (score <=0.75); partially controlled asthma (score 0.75-1.5), or not well controlled asthma (score >1.5). A change in ACQ-5 score of 0.5 is considered the MCID. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Number of Participants Analyzed with Treatment Utilization Pattern between Part 2 Cohorts A1 and A2
Prazo: Part 2: At Weeks 52 and 104
|
Treatment utilization will include systemic corticosteroids (SCS), ICS, and short-acting beta agonists (SABA). Number of participants with various treatment utilization pattern will be assessed and reported. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Descriptive Statistical Analysis of Difference in Change in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV₁) between Part 2 Cohorts B1 and Cohort B2
Prazo: Part-2: At Weeks 52 and 104
|
Pre-BD FEV₁ is the forced expiratory volume in 1 second measured by spirometry prior to bronchodilator administration. |
Part-2: At Weeks 52 and 104
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Parte 1: Número de Participantes Caracterizados pelos Seus Dados Demográficos e Características Clínicas
Prazo: Parte 1: 12 meses antes da inscrição no estudo
|
Parte 1: 12 meses antes da inscrição no estudo
|
|
|
<string>Parte 1: Número de participantes caracterizados pela sua carga de doença, estado de saúde e experiências de tratamento</string>
Prazo: Parte 1: Dos 12 meses anteriores à inscrição no estudo
|
Parte 1: Dos 12 meses anteriores à inscrição no estudo
|
|
|
Parte 1: Número de Participantes Caracterizados pelo Uso de Medicação
Prazo: Parte 1: Dos 12 meses anteriores à inclusão no estudo
|
Parte 1: Dos 12 meses anteriores à inclusão no estudo
|
|
|
Parte 1: Número de Participantes Caracterizados pelas Suas Influências do Estilo de Vida e Ambientais
Prazo: Parte 1: 12 meses antes da inscrição no estudo
|
Parte 1: 12 meses antes da inscrição no estudo
|
|
|
Parte 1: Número de Participantes Caracterizados pela Utilização de Corticosteroides Inalados e Sistémicos
Prazo: Parte 1: Desde 12 meses antes da inscrição no estudo
|
Parte 1: Desde 12 meses antes da inscrição no estudo
|
|
|
Parte 1: Número de Participantes Caracterizados pela Utilização de Recursos de Saúde (HCRU)
Prazo: Parte 1: Dos 12 meses anteriores à inscrição no estudo
|
Parte 1: Dos 12 meses anteriores à inscrição no estudo
|
|
|
Parte 2: Caracterização Descritiva Incluindo Sociodemografia e Características da Doença e História do Tratamento.
Prazo: Parte 2: No início do estudo
|
Parte 2: No início do estudo
|
|
|
Parte 2: Taxas de Exacerbação Anualizadas na Semana 52 e 104
Prazo: Parte 2: nas Semanas 52 e 104
|
Parte 2: nas Semanas 52 e 104
|
|
|
Parte 2: Número de Participantes Analisados para Alterações na Carga de Corticosteroides Inalados e Sistémicos
Prazo: Parte 2: Desde o início até à semana 104
|
Parte 2: Desde o início até à semana 104
|
|
|
Parte 2: Alterações no Nível de Biomarcador
Prazo: Parte 2: Nas Semanas 52 e 104
|
Parte 2: Nas Semanas 52 e 104
|
|
|
Part 1: Physician-Reported Outcomes to Characterize Physician Perspectives
Prazo: Part 1: From 12 months prior to study enrollment
|
The treatment preferences for participant profiles, an assessment of perceived disease burden on participants, an evaluation of barriers to optimal treatment, and treatment adherence and persistence will be collected from the main treating physician. |
Part 1: From 12 months prior to study enrollment
|
|
Part 1: Change From Baseline in Patient Global Impression of Severity (PGIS) Score
Prazo: Part 1: From 12 months prior to study enrollment
|
The PGIS is a single question asking the participant to rate their severity and symptom control. The PGIS is a 5-point ordinal scale ranging from 1 (No symptoms) to 5 (Very severe symptoms). Higher scores indicate greater symptom severity. |
Part 1: From 12 months prior to study enrollment
|
|
Part 1: Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Score
Prazo: Part 1: From 12 months prior to study enrollment
|
The WPAI-Asthma is an Asthma-specific, patient-reported measure of work absenteeism, work presenteeism (reduced productivity while working due to illness), total work productivity loss (absenteeism plus presenteeism), and overall activity impairment over the prior 7 days. The WPAI-Asthma questionnaire score represents the percentage of impairment, from 0 to 100%. Higher scores represent greater impairment and less productivity. |
Part 1: From 12 months prior to study enrollment
|
|
Part 2: Changes From Baseline to Week 104 in Pre and Post Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Prazo: Part 2: From baseline to week 52 and week 104
|
FEV1 will be measured in Liters. Change from baseline: mean of (value of observed FEV1 at treatment duration minus baseline value). |
Part 2: From baseline to week 52 and week 104
|
|
Part 2: Number of Participants With Significant Changes in Asthma Treatment Patterns at Week 52 and Week 104
Prazo: Part 2: From baseline to week 52 and week 104
|
Changes in treatment patterns including use of SCS, ICS, other asthma therapies, and rescue medication. Treatment escalation (for example [e.g.], ICS dose changes, addition of asthma therapies, or biologic prescription), treatment adherence, and treatment persistence will be assessed from baseline to Week 52 and Week 104 in participants with Asthma. |
Part 2: From baseline to week 52 and week 104
|
|
Part 2: Changes in Physician Global Assessment of Asthma Severity, Symptom Control and Comorbidities (PhGIS)
Prazo: Part 2: From baseline to week 52 and week 104
|
Asthma severity, asthma control, and comorbidity will be assessed using three global impression of severity items: PhGIS - asthma severity. PhGIS - asthma control, and PhGIS - comorbidity. |
Part 2: From baseline to week 52 and week 104
|
|
Part 2: Number of Participants With Comorbidities and Burden of Comorbidities Based on the Participant Survey Using the PGIS scale
Prazo: Part 2: At Weeks 52 and 104
|
The PGIS is a single question asking the participant to rate their severity and symptom control. The PGIS is a 5-point ordinal scale ranging from 1 (No symptoms) to 5 (Very severe symptoms). Higher scores indicate greater symptom severity. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Number of Participants With Comorbidities and Burden of Comorbidities Based on the Physician Survey Using the PhGIS Scale
Prazo: Part 2: At Weeks 52 and 104
|
Asthma severity, asthma control, and comorbidity will be assessed using three global impression of severity items: PhGIS - asthma severity. PhGIS - asthma control, and PhGIS - comorbidity. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Changes in Physician-reported HCRU (Hospitalizations, Outpatient and Emergency Visits)
Prazo: Part 2: From baseline to week 52 and week 104
|
Data about HCRU associated with medical encounters will be collected by physicians from medical records. The data collected will include setting, department, type of specialist, the reasons and duration of hospitalizations, outpatient and emergency room (ER) visits. |
Part 2: From baseline to week 52 and week 104
|
|
Part 2: Changes in Patient-Reported Outcomes to Characterize Disease Evolution
Prazo: Part 2: At Weeks 52 and 104
|
PROs used will include but not limited to ACQ-5, mini-AQLQ. ACQ-5 questions are scored on a 6-point scale (0 = good control, 6 = poor control), Mean of the five responses is the overall score. Scores are then classified into three groups as having well-controlled asthma (score <= 0.75); partially controlled asthma (score 0.75-1.5), or not well controlled asthma (score >1.5). AQLQ includes 32 items, The mini-AQLQ is a reduced version of the AQLQ which includes 15 items. The questions correspond to 4 dimensions of health: symptoms (5 items), limitation of usual activities (4 items), emotional function (3 items) and environmental stimuli (3 items). The response options for each item are on an equidistant scale of 7 points, where 1 corresponds to the maximum disability and 7 to the absence of disability. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Changes in Participant Survey Response
Prazo: Part 2: From baseline to week 52 and week 104
|
Participant survey collecting demographics, clinical characteristics, disease burden, health status, treatment experiences, medication use and burden, work and school impacts, lifestyle and environmental influences, impacts on daily life, PGIS for each comorbidity and burden of comorbidities, inhaled and systemic corticosteroid burden (frequency of use, routes of administration, treatment satisfaction), and HCRU office visits, hospitalizations, outpatient and emergency visits will be collected from medical records. |
Part 2: From baseline to week 52 and week 104
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- PIR21191
- 2025-524916-13-00 (Ctis)
- U1111-1336-5183 (Identificador de registro: ICTRP)
- 2025 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .